Pramlintide improves glucose control in type 1 diabetes

Pramlintide improves glucose control in type 1 diabetes
The addition of pramlintide, an analog of the naturally-occurring β-cell peptide amylin, before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external closed-loop artificial pancreas system, according to a study published online June 18 in Diabetes Care.

(HealthDay) -- The addition of pramlintide, an analog of the naturally-occurring β-cell peptide amylin, before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external closed-loop artificial pancreas system, according to a study published online June 18 in Diabetes Care.

To examine whether preprandial injections of pramlintide would improve postprandial glycemia by delaying gastric emptying, Stuart A. Weinzimer, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues treated eight patients with type 1 diabetes (15 to 30 years old) with a closed-loop delivery system for 24 hours either alone or plus preprandial injections of 30 µg pramlintide.

The researchers found that the addition of pramlintide significantly increased the mean time to peak (2.5 versus 1.5 hours). The addition of pramlintide also significantly reduced the mean magnitude of glycemic excursion (88 versus 113 mg/dL), with the reduction being particularly pronounced at lunch and dinner, when premeal insulin concentrations were higher.

"Pramlintide delayed the time to peak postprandial blood glucose and reduced the magnitude of prandial blood glucose excursions," Weinzimer and colleagues conclude. "Beneficial effects of pramlintide on closed-loop may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast."

Two authors are employees of Medtronic , which provided equipment for the study. Two additional authors are consultants/advisors to Medtronic MiniMed and Animas Corporation.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ADA: Hypo-hyperglycemia minimizer system feasible

date Jun 12, 2012

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes ...

Absolute incretin effect reduced in type 2 diabetes

date Jun 25, 2012

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase ...

Recommended for you

Faster heart rate linked to diabetes risk

date May 22, 2015

An association between resting heart rate and diabetes suggests that heart rate measures could identify individuals with a higher future risk of diabetes, according to an international team of researchers.

EBV co-infection may boost malaria mortality in childhood

date May 21, 2015

Many people who live in sub-Saharan Africa develop a natural immunity to malaria, through repeated exposure to Plasmodium parasites. Even so, the disease kills close to half a million children per year, according ...

Three important things you didn't know about diabetes

date May 21, 2015

When we think of diabetes, we tend to think of rich people with poor lifestyles. A chronic disease linked with obesity, heart disease and worse outcomes for some infectious diseases, diabetes tends to be ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.